<DOC>
	<DOCNO>NCT01778244</DOCNO>
	<brief_summary>Almost antipsychotic induce dyslipidemia , treatment establish . Metformin improve lipid level obese patient . The investigator conduct randomized , placebo-controlled study test efficacy metformin antipsychotic-induced dyslipidemia .</brief_summary>
	<brief_title>Metformin Treatment Antipsychotic-induced Dyslipidemia</brief_title>
	<detailed_description>The study design double-blind randomized control trial , research assessor patient intend blind intervention status . The staff member perform assessment involve implement aspect intervention.162 patient randomize one two 24-week individual treatment : metformin ( 1000mg/day ) placebo . Medications provide double-blind fashion.The assessment include lipid level , body weight , body mass index , fast glucose , fast insulin insulin resistance index .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnostic Statistical Manual Mental DisorderFourth Edition ( DSMⅣ ) criteria schizophrenia dyslipidemia antipsycotic treatment duration illness le 12 month take one antipsychotic stable outpatient total score Positive Negative Syndrome Scale ( PANSS ) ≤60 . liver renal disease pregnant lactate woman cardiovascular disease hypertension diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>schizophrenia ; dyslipidemia</keyword>
</DOC>